Covered recipient · General Payments record
MAXWELL Q NYCE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2022–2024
$526.27
- Reported across 22 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $347.15 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $131.64 | 7 |
| Lundbeck LLC | $37.58 | 1 |
| Lilly USA, LLC | $32.06 | 2 |
| Mirum Pharmaceuticals, Inc. | $27.62 | 1 |
| SK Life Science, Inc. | $25.74 | 1 |
| Neurocrine BioSciences, Inc. | $24.49 | 1 |
| LivaNova USA, Inc. | $19.71 | 1 |
| Abbott Laboratories | $18.52 | 1 |
| Celgene Corporation | $14.94 | 1 |
| Teva Pharmaceuticals USA, Inc. | $14.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $18.52 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125208267 | CMS |
| ABBVIE INC. | $6.01 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138532 | CMS |
| ABBVIE INC. | $14.91 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138534 | CMS |
| ABBVIE INC. | $31.97 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138536 | CMS |
| ABBVIE INC. | $22.25 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138538 | CMS |
| ABBVIE INC. | $16.75 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138540 | CMS |
| ABBVIE INC. | $22.11 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138542 | CMS |
| ABBVIE INC. | $17.64 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105138544 | CMS |
| Celgene Corporation | $14.94 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101152113 | CMS |
| Lilly USA, LLC | $17.43 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135185879 | CMS |
| Lilly USA, LLC | $14.63 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135180359 | CMS |
| LivaNova USA, Inc. | $19.71 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152793155 | CMS |
| Lundbeck LLC | $37.58 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145951735 | CMS |
| Mirum Pharmaceuticals, Inc. | $27.62 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1123323531 | CMS |
| Neurocrine Biosciences, Inc. | $24.49 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150841544 | CMS |
| SK Life Science, Inc. | $25.74 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154123471 | CMS |
| Teva Pharmaceuticals USA, Inc. | $14.85 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151715698 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.